



Mitsubishi Tanabe Pharma Canada (MTP-CA) is deeply committed to bringing RADICAVA™ (edaravone) to people living with ALS. At this time, the date of commercial availability in Canada has not been determined.

We currently are navigating the reimbursement process required to provide access to prescription medicines in Canada. Important discussions are ongoing. Once the necessary steps are completed, we will finalize the timing for RADICAVA's availability and will share that information through various communication channels.